RNS Number: 9391 Z Nuformix PLC 24 September 2020 Nuformix plc. Cambridge, UK- 24 September 2020: Nuformix plc, a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop novel medicines to provide enhanced benefit, announces it has signed an exclusive option agreement with Oxilio Ltd..
RNS Number: 7285 W Nuformix PLC 20 August 2020 Nuformix plc. Cambridge, UK- 20 August 2020: Nuformix plc announces that all resolutions proposed at its Annual General Meeting held today were duly passed on a poll, the results of which are set out below:. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6183 W Nuformix PLC 19 August 2020 Nuformix plc. Cambridge, UK- 19 August 2020: Nuformix plc, a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop new novel medicines to provide enhanced benefit, announces results from the pre-clinical pilot study and evaluation of its NXP004...
RNS Number: 3580 U Nuformix PLC 28 July 2020 Nuformix plc. Annual Report and Accounts for the year ended 31 March 2020. Cambridge, UK- 28 July 2020: Nuformix plc, announces that today it has released the following documents:.
RNS Number: 6873 T Nuformix PLC 22 July 2020 Nuformix plc. Preliminary Results for the year ended 31 March 2020. Cambridge, UK- 22 July 2020: Nuformix plc, a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop new novel medicines to provide enhanced benefit, is pleased to announce its preliminary...
RNS Number: 7234 R Nuformix PLC 01 July 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5781 Q Nuformix PLC 22 June 2020 22 June 2020. Nuformix announces the resignation of Dr. Dan Gooding, Chief Executive Officer.
RNS Number: 0473 O Nuformix PLC 27 May 2020 Nuformix and VistaGen Announce Agreement to Develop Novel Patentable Cocrystal Forms of AV-101 for Treatment of Multiple CNS Conditions. Novel Cocrystal Form of AV-101 Administered with Probenecid. Cambridge, UK- 27 May 2020: Nuformix plc, the pharmaceutical development company focused on unlocking the...
RNS Number: 0476 O Nuformix PLC 27 May 2020 27 th May 2020. Nuformix, the pharmaceutical development company f ocused on unlocking the therapeutic potential and value of known drugs announces the following business update:. ·As China has emerged from lock-down, it is clear that the protracted fall-out between Newsummit Biopharma "NSB" and its parent company will...
RNS Number: 1690 M Nuformix PLC 06 May 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7907 I Nuformix PLC 03 April 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1002 I Nuformix PLC 30 March 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5007 F Nuformix PLC 09 March 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4951 F Nuformix PLC 09 March 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Nuformix plc
NFX.L
Nuformix plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    469.47M

Featured Media

Company Profile

Nuformix is a pharmaceutical development company using cocrystal technology, unlocking the therapeutic potential of approved drugs with lead programmes in oncology supportive care and fibrosis.

Classification

Market Indices-
Watchlist